Biggest News Aggregation in the World
📰 Statement Regarding News

Page 55 - Statement Regarding News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Statement Regarding. Real-time updates on events, politics, business and more.

EQS-News: DEFENCE THERAPEUTICS IS GRANTED PATENTS IN JAPAN AND ISRAEL EXPANDING ITS NOVEL ADC PLATFORM TECHNOLOGY IN THE FAST GROWING ANTIBODY-DRUG CONJUGATES MARKET

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE THERAPEUTICS IS GRANTED PATENTS IN JAPAN AND ISRAEL EXPANDING ITS NOVEL ADC PLATFORM TECHNOLOGY IN THE FAST GROWING ANTIBODY-DRUG CONJUGATES MARKET 29.09.2022 / 08:00 CET/CEST The issuer is solely responsible for the conten...
British Columbia Sebastien Plouffe Defence Therapeutics Inc Company Accum Japan Patent Office News Service

Defence Therapeutics Inc.: Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market

Vancouver, British Columbia--(Newsfile Corp. - September 29, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company
United Kingdom British Columbia Sebastien Plouffe Defence Therapeutics Inc Company Accum Japan Patent Office

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

EQS-News: Defence Therapeutics Inc.: BREAKTHROUGH RESULTS WITH ACCUM(TM) A1-REPROGRAMMED MSC, MESENCHYMAL STEM CELLS, IN A NOVEL VACCINE CURED 80% OF ANIMALS WITH PRE-ESTABLISHED LYMPHOMA

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous Defence Therapeutics Inc.: BREAKTHROUGH RESULTS WITH ACCUM(TM) A1-REPROGRAMMED MSC, MESENCHYMAL STEM CELLS, IN A NOVEL VACCINE CURED 80% OF ANIMALS WITH PRE-ESTABLISHED LYMPHOMA 21.09.2022 / 08:00 CET/CEST The issuer is solely resp...
British Columbia Sebastien Plouffe Moutih Rafei Defence Therapeutics Inc Mcgill University News Service

Defence Therapeutics Inc.: Breakthrough Results with Accum A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma

Vancouver, British Columbia--(Newsfile Corp. - September 21, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company
United Kingdom British Columbia Sebastien Plouffe Moutih Rafei Defence Therapeutics Inc Mcgill University

DEFENCE THERAPEUTICS APPLAUDS UNITED STATES PRESIDENT BIDEN CANCER MOONSHOT INITIATIVE

EQS-News: Defence Therapeutics Inc. / Key word(s): MiscellaneousDEFENCE THERAPEUTICS APPLAUDS UNITED STATES PRESIDENT BIDEN CANCER MOONSHOT INITIATIVE 19.09.2022 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CSE: DTC          &...
United States British Columbia Johnf Kennedy Sebastien Plouffe Joe Biden Defence Therapeutics Inc

EQS-News: DEFENCE THERAPEUTICS APPLAUDS UNITED STATES PRESIDENT BIDEN CANCER MOONSHOT INITIATIVE

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE THERAPEUTICS APPLAUDS UNITED STATES PRESIDENT BIDEN CANCER MOONSHOT INITIATIVE 19.09.2022 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. CSE: DTC             FSE: DTC             USO.
United States British Columbia Johnf Kennedy Sebastien Plouffe Joe Biden Defence Therapeutics Inc

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science